Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Perflutren lipid microspheres, marketed under the brand name Definity, is an ultrasound contrast agent consisting of octafluoropropane (perflutren) gas encapsulated within a lipid shell. The lipid shell is composed of dipalmitoylphosphatidylcholine (DPPC), methylpoly(ethylene glycol) dipalmitoylphosphatidylethanolamine (MPEG5000 DPPE), and dipalmitoylphosphatidic acid (DPPA). While it is FDA-approved for use in echocardiography to opacify the left ventricular chamber and improve the delineation of the endocardial border, it is being investigated by Thomas Jefferson University in an early phase 1 clinical trial for patients with breast cancer. In this investigational setting, contrast-enhanced ultrasound (CEUS) using these microspheres is employed to noninvasively estimate interstitial fluid pressure (IFP) by analyzing subharmonic signals, which may provide critical insights into the tumor microenvironment and treatment response.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Perflutren lipid microspheres (Thomas Jefferson University).